Abstract:Abstract Objectives Explore co-morbidity profile of persons with chronic myeloid leukemia (CML) in chronic phase receiving tyrosine kinase-inhibitor (TKI) therapy. Identify the effect of co-morbidity(ies) on response to TKI-therapy, patient-reported satisfaction with TKI-therapy, adverse impact on patients' work and daily lives and health-related quality-of life (HRQoL). Methods We distributed an anonymous, non-interventional, cross-sectional multiple choice questionnaire to ascertain common co-morbidities to adults with CML. Eligibility criteria included persons with chronic phase CML receiving TKI treatment >=3 months. Satisfaction with TKI-therapy was analyzed as: (1) high satisfaction; (2) satisfaction; (3) dissatisfaction; and (4) extreme dissatisfaction. Respondent-reported TKI-therapy-related adverse impact on work and daily life was assessed as Y/N. The SF-36 Health Survey was used to measure HRQOL and used to develop 2 summary scores of physical component summary (PCS) and mental component summary (MCS). Results Data from 1,143 respondents were analyzed. 725 (63%) were male. Median age was 42 years (range, 18-88 years). 944 (83%) started TKI-therapy <6 months after diagnosis and 868 (76%) were currently on imatinib. 742 (65%) were receiving branded TKIs drugs including Glivec®, Tasigna® and Sprycel®. Median TKI-therapy-duration was 29 months (range, 3-182 months). 878 (78%) achieved a complete cytogenetic response (CCyR) and 479 (43%), a complete molecular response (CMR). 307 (27%) had >=1 co-morbidity and 79 (7%) had >=2 co-morbidities including hypertension (30%), diabetes (21%), heart (12%), gastro-intestinal (12%) liver (12%), kidney (8%), cerebro-vascular (7%) and lung diseases (6%), thrombosis (1%), other cancer (8%) and other (15%). Increasing age (OR=2.0; 95% CI, 1.7, 2.2; p<0.001) and starting TKI treatment >6 months from diagnosis (OR=1.5; [1.0, 2.1]; p=0.040) were associated with co-morbidity(ies) in multivariate analyses. 97 respondents (32%) with co-morbidity(ies) were receiving drugs in addition to TKIs. Respondent satisfaction levels with TKI-therapy were: (1) high satisfaction, 37%; (2) satisfaction, 53%; (3) dissatisfaction, 8%; and (4) extreme dissatisfaction, 2%. 497 respondents (43%) reported TKI-therapy-related negatively impacted work and daily life. There was no significance between type of TKI, achieving CCyR or CMR and respondent satisfaction with TKI-therapy. Co-morbidity profile was significantly-associated with respondent-reported >= satisfaction with TKI-therapy: no co-morbidity, 759 (91%); cardio-cerebral vascular diseases (CCVD), metabolic syndrome and/or other cancers, 176 (93%); and other benign diseases, 99 (85%; p-value for trend=0.056). Co-morbidity profile was also significantly-associated with respondent-reported TKI-therapy-related adverse impact on work and daily life: no co-morbidity, 363 (47%); CCVD, metabolic syndrome and/or other cancers, 68 (41%); and other benign diseases, 66 (65%; p-value for trend <0.001). Co-morbidity profile was also significantly correlated with HRQoL outcomes. PCS score for each co-morbidity profile were: no co-morbidity, 47.9+/-8.7; CCVD, metabolic syndrome and/or other cancers, 44.4+/-9.8; and other benign diseases, 43.2+/-9.9; p<0.001. MCS score for each co-morbidity profile were: no co-morbidity, 49.9+/-10.9; CCVD, metabolic syndrome and/or other cancers, 52.3+/-10.7; and other benign diseases, 46.0+/-11.2; p<0.001. (Figure) Multivariate analyses showed co-morbidity profile was an independent factor affecting patients' work and daily life (OR=1.4; [1.4-1.9]; p=0.008), PCS (OR=1.4; [1.2-1.7]; p=0.001) and MCS (OR=1.5; [1.2-1.9]; p=0.002). Conclusions The survey showed that 27% (24, 29%) of persons with chronic phase CML receiving TKI-therapy had co-morbidity(ies). CCVD and/or metabolic syndrome were the most common. Co-morbidity(ies) were more common in older subjects. Co-morbidity profile significantly influenced patients' work, daily life and HRQoL. Assessing co-morbidity profile in persons with CML is important to identify persons needing improvement of quality-of-care and HRQoL. Figure 1 Satisfaction, adverse impact on work and daily life by co-morbidity profile Figure 1. Satisfaction, adverse impact on work and daily life by co-morbidity profile Figure 2 Health-related quality of life by co-morbidity profile Figure 2. Health-related quality of life by co-morbidity profile Disclosures No relevant conflicts of interest to declare.

Comorbidity Profile and Its Impact on Reported Outcome in Chinese Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Tyrosine Kinase-Inhibitor Therapy

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Health-related Quality of Life in Children with Chronic Myeloid Leukemia in the Chronic Phase

A Survey on Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia in China: from Patients' Perspective

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

[Patient Reported Outcome of Tyrosine Kinase Inhibitor Related Side Effects and Their Impact on Daily Life in Chinese Patients with Chronic Myeloid Leukemia in the Chronic Phase].

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Impact of Socio-Demographic Co-Variates on Prognosis, Tyrosine Kinase-Inhibitor Use and Outcomes in Persons with Newly-Diagnosed Chronic Myeloid Leukaemia

[Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].

Higher Out-of-pocket Expenses for Tyrosine Kinase-Inhibitor Therapy is Associated with Worse Health-Related Quality-of-life in Persons with Chronic Myeloid Leukemia

Treatment Status of Tyrosine Kinase Inhibitors in Chinese Patients with Chronic Myeloid Leukemia in 2020

Combination of Socio-Demographic and Clinical Co-Variates for Predicting Treatment Responses and Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase

[Analysis on Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia in the Real World: Experience from Single Center].

Variables Associated with Self-Reported Anxiety and Depression Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.

Health-Related Quality of Life (HRQOL) in Patients (pts) with Tyrosine Kinase Inhibitor- (Tki)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

P684: a multicenter retrospective study in china: clinical characteristics and prognosis of patients with cml-cp treated with different tyrosine kinase inhibitors

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Health-Related Quality Of Life Of Community Thyroid Cancer Survivors In Hangzhou, China

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

[The Impact of Glivec Related Side Effects on Daily Life in Chinese Patients with Chronic Myeloid Leukemia in the Chronic Phase].

Variables Associated with Patient-Reported Outcomes in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy